PharmiGENE

The global leader of pharmacogenetic tests



Product


Patented PGx detection reagent

Service

Diagnostic reagent OEM/ODM/CDMO









service@pharmigene.com



9 7F., No. 302, Jianguo 1st Rd., Xinzhuang Dist., New Taipei City 242047, Taiwan





Pharmigene is established in 2005 and located in Taipei, Taiwan.

Our goal is to innovate and commercialize diagnostic tests that enable individuals to be better informed about their genomic makeup and to make decisions that better their health.


We have licensed exclusive world-wide rights and transferred key know-how from Academia Sinica relating to the genetic markers that are associated with adverse drug reactions caused by several popular drugs. We have obtained ISO 13485 and GMP certifications, and are manufacturing our DNA genetic tests under the most stringent guideline. In developing our DNA genetic tests, we also have validated our tests with clinical studies that involved hundreds and thousands of patients. Today our certified DNA genetic tests are available worldwide.

What Pharmigene products offer

- 1000 + real DNA samples includes Caucasians and Asians, and tested & validated by DNA sequencing.
- Over 99+% sensitivity & over 99% specificity compared with sequencing data.
- Genomic DNA to results in ~2 hours.
- Compatible with most real-time PCR systems.
- Unique design to perform different genotyping tests at one time.



Mix & Match Design...



Making your real-time PCR testing easier & faster!

HLA-B*1502



"Pharmacogenomics is the study of how genes affect a person's response to drugs. This relatively new field combines pharmacology (the science of drugs) and genomics (the study of genes and their functions) to develop effective, safe medications and doses that will be tailored to a person's genetic makeup."

-What is pharmacogenomics? https://ghr.nlm.nih.gov/primer/genomicresearch/pharmacogenomics

Before, drug can only be prescribed by indications



Now, drug can be prescribed not only by indication but also by pharmacogenomics result



How Pharmigene PGx products work




Sample collection Buccal swab or blood



DNA extraction



Target amplification by qPCR systems





Result analysis

Hypersensitivity

Drug Sensitivity

Drug sensitivity is the abnormal reaction of human immune system caused by medication. Any medication may has the possibility to induce the immune storm - drug sensitivity. The symptoms of drug sensitivity is vary like hives, rash or fever. Sometimes, server events such as Stevens-Johnson syndrome or Toxic epidermal necrolysis can occur and may cause death.

Product Name	Catalog #	Pack Size	Sample Size	Regulation	Description
	PG-1502C-024	24 reactions	10 samples	Taiwan FDA China NMPA Singapore HSA	HLA-B*1502 gene has been found a strong association with Carbamazepine induced severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson Syndrome and Toxic Epidermal
PG1502 Detection Kit	PG-1502C-048	48 reactions	20 samples		
	PG-1502C-096	96 reactions	40 samples	Thailand FDA CE IVD	Necrolysis. HLA-B*1502 gene is common in southeast Asia, South China and Taiwan.
	PG-1502A-012	12 reactions	10 samples		HLA-B*1502 gene has been found a strong association with Carbamazepine induced severe
PG1502 Detection Reagent	PG-1502A-024	24 reactions	20 samples	USA (ASR)	cutaneous adverse reactions (SCARs) such as Stevens-Johnson Syndrome and Toxic Epidermal
	PG-1502A-048	48 reactions	40 samples		Necrolysis. HLA-B*1502 gene is common in southeast Asia, South China and Taiwan.
	PG-1513C-012	12 reactions	10 samples		HLA-B*1513 gene is common (8~15%) in south-east
PG1502 Companion Kit-RT	PG-1513C-024	24 reactions	20 samples	RUO	Asians. Using this kit to distinguish HLA-B*1502 and HLA-B*1513 can help physicians identifying the patient from south-east Asia who has high risk to
	PG-1513C-048	48 reactions	40 samples		take Carbamazepine.
PG5801 Detection Kit	PG-5801C-024	24 reactions	10 samples	Taiwan FDA China NMPA Korea MFDS Singapore HSA Thailand FDA CE IVD	HLA-B*5801 gene has been found a strong association with Allopurinol induced severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis.
	PG-5801C-048	48 reactions	20 samples		
	PG-5801C-096	96 reactions	40 samples		
	PG-5801A-012	12 reactions	10 samples	USA (ASR)	HLA-B*5801 gene has been found a strong association with Allopurinol induced severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis.
PG5801 Detection Reagent	PG-5801A-024	24 reactions	20 samples		
	PG-5801A-048	48 reactions	40 samples		
	PG-5701C-024	24 reactions	10 samples	Thailand FDA CE IVD	HLA-B*5701 gene has been found a strong association with Abacavir, a drug for HIV treatment, induced hypersensitivity.
PG5701 Detection Kit	PG-5701C-048	48 reactions	20 samples		
	PG-5701C-096	96 reactions	40 samples		,, ,
PG5701 Detection Reagent	PG-5701A-012	12 reactions	10 samples		HLA-B*5701 gene has been found a strong association with Abacavir, a drug for HIV treatment, induced hypersensitivity.
	PG-5701A-024	24 reactions	20 samples	USA (ASR)	
	PG-5701A-048	48 reactions	40 samples		,, ,
PG3101 Detection Kit	PG-3101C-024	24 reactions	10 samples	RUO	HLA-A*3101 gene has been found an association with Carbamazepine induced severe cutaneous adverse reactions (SCARs). HLA-A*3101 gene is common in Japan, Korea, Europe and America.
	PG-3101C-048	48 reactions	20 samples		
	PG-3101C-096	96 reactions	40 samples		

PG-3101 Detection Reagent PG-3101A-012 12 reactions 10 samples PG-3101A-022 24 reactions 20 samples PG-3101A-024 24 reactions 20 samples PG-3101A-024 24 reactions 10 samples PG-3101C-024 24 reactions 10 samples PG-3101A-024 24 reactions 10 samples PG-3101A-024 24 reactions 10 samples PG-3101C-024 24 reactions 10 samples PG-3101A-024 24 reacti	Product Name	Catalog #	Pack Size	Sample Size	Regulation	Description
PG3010 Detection Reagent PG-3101A-024 24 reactions 40 samples PG-3101A-046 48 reactions 40 samples PG-3101C-046 48 reactions 40 samples PG-3101C-046 48 reactions 20 samples PG-3101C-046 48 reactions 20 samples PG-3101C-046 48 reactions 40 samples PG-3101A-042 42 reactions 40 samples PG-3101C-044 48 reactions 40 samples PG-5101C-044 48 reactions 40 samples PG-5101C-046 48 reactions PG-5101A-048 48 reactions PG-6101A-048 48 reactions PG-6101		PG-3101A-012	12 reactions	10 samples	USA (ASR)	Carbamazepine induced severe cutaneous adverse
PG3001 Detection Kit PG-1301C-024 Z4 reactions Detection Kit PG-1301C-024 Z4 reactions Detection Kit PG-1301C-088 A8 reactions Detection Kit PG-1301C-096 PG-1301C-096 PG-1301A-012 Z1 reactions Detection Reagent PG-1301A-012 PG-1301A-024 Z4 reactions Detection Reagent PG-1301A-024 PG-1301A-024 PG-1301A-024 Z4 reactions Detection Reagent PG-1301A-024 PG-1301A-0		PG-3101A-024	24 reactions	20 samples		
Detection Kit PG-130IC-048 PG-130IC-048 PG-130IC-056 PG-130IC-076 PG-130IA-012 PG-130IA-048 PG-1		PG-3101A-048	48 reactions	40 samples		Japan, Korea, Europe and America.
PG-1301C-Q48 48 reactions 20 samples	PG1301	PG-1301C-024	24 reactions	10 samples		
PG1301 PG-1301A-012 12 reactions 10 samples PG-1301A-024 24 reactions 20 samples PG-1301A-024 24 reactions 40 samples PG-1301A-048 48 reactions 20 samples PG-101C-024 24 reactions 40 samples PG-5101C-024 24 reactions 40 samples PG-5101C-026 96 reactions 40 samples PG-5101A-012 12 reactions 10 samples PG-5101A-012 12 reactions 10 samples PG-5101A-012 12 reactions 20 samples PG-5101A-012 12 reactions 40 samples PG-5101A-012 12 reactions 20 samples PG-51	Detection Kit	PG-1301C-048	48 reactions	20 samples	RUO	
PG1301 Detection Reagent PG-1301A-024 PG-1301A-024 PG-1301A-024 PG-1301A-048 PG-1301A-048 PG-1301A-048 PG-5101C-024 PG-5101C-024 PG-5101C-024 PG-5101C-024 PG-5101C-026 PG-510		PG-1301C-096	96 reactions	40 samples		
Detection Reagent PG-1301A-024 24 reactions 20 samples PG-5101C-024 24 reactions 10 samples PG-5101C-026 48 reactions 20 samples PG-5101C-026 96 reactions 40 samples PG-5101C-026 96 reactions 20 samples PG-5101A-022 12 reactions 20 samples PG-5101A-024 24 reactions 40 samples PG-6101A-024 12 reactions 10 samples PG-6101A-024 24 reactions 20 samples PG-6101A-024 24 reactions 20 samples PG-1001A-024 24 reactions 20 samples PG-1001A-024 24 reactions 20 samples PG-1001A-024 24 reactions 40 samples PG-1001A-024 24 reactions 20 samples PG-1001A-024 24 reactions 40 samples PG-3802C-024 24 reactions 20 samples PG-3802C-024 24 reactions 20 samples PG-3802C-026 48 Reactions 40 samples PG-3802C-036 48 reactions 20 samples PG-3802C-036 48 reactions 40 samples PG-3801C-036 48 reactions 40 samples PG-3901C-036 48 reactions 40 s	D01001	PG-1301A-012	12 reactions	10 samples		HI A-R*1301 gene has been found an association with
PG-5101C-024 24 reactions 10 samples PG-5101C-024 24 reactions 20 samples RUO H.A.B*5101 gene has been found an association with Phenytion and Lamotrigine induced severe cutaneous adverse reactions (SCARs).		PG-1301A-024	24 reactions	20 samples	USA (ASR)	Co-trimoxazole (Baktar), Dapsone and Phenytoin
PG-5101 Detection Kit PG-5101C-048		PG-1301A-048	48 reactions	40 samples		
PG-5101C-048		PG-5101C-024	24 reactions	10 samples		LII A D*E101 gane has been found an association with
PG-5101C-096 96 reactions 40 samples PG-5101A-012 12 reactions 10 samples PG-5101A-024 24 reactions 20 samples PG-5101A-024 24 reactions 40 samples PG-101A-048 48 reactions 40 samples PG-101A-049 24 reactions 10 samples PG-101A-040 24 reactions 10 samples PG-101A-040 24 reactions 20 samples PG-101A-040 48 reactions 40 samples PG-101A-040 48 reactions 40 samples PG-101A-040 48 reactions 40 samples PG-3802C-040 48 reactions 40 samples PG-3802C-040 48 reactions 20 samples PG-3802C-048 48 reactions 20 samples PG-3802C-096 96 reactions 40 samples PG-3802C-096 48 reactions 20 samples PG-3802C-096 48 reactions 20 samples PG-3802C-096 48 reactions 20 samples PG-3802C-096 48 reactions 40 samples PG-3901C-094 48 reactions 40 samples PG-3901C-096 96 reactions 40 samples P		PG-5101C-048	48 reactions	20 samples	RUO	Phenytion and Lamotrigine induced severe
PG-5101A-024 24 reactions 20 samples USA (ASR) HLA-B*5101 gene has been found an association with Phenytion and Lamotrigine induced severe cutaneous adverse reactions (SCARs). PG-5101A-048 48 reactions 40 samples PG-IC01A-012 12 reactions 20 samples PG-IC01A-024 24 reactions 20 samples PG-IC01A-024 24 reactions 40 samples PG-IC01A-048 48 reactions 40 samples PG-3802C-024 24 reactions 20 samples PG-3802C-024 24 reactions 20 samples PG-3802C-026 48 reactions 20 samples PG-3802C-096 96 reactions 40 samples PG-3802C-096 96 reactions 20 samples PG-3802A-012 12 reactions 10 samples PG-3802A-048 24 reactions 20 samples PG-3802A-048 24 reactions 20 samples PG-3802A-048 24 reactions 20 samples PG-3901C-024 24 reactions 10 samples PG-3901C-026 48 reactions 20 samples PG-3901C-096 96 reactions 40 samples PG-3901		PG-5101C-096	96 reactions	40 samples		
PG-5101A-024 24 reactions 20 samples USA (ASR) Phenytion and Lamotrigine induced severe cutaneous adverse reactions (SCARs). PG-5101A-048 48 reactions 40 samples PG-101A-048 24 reactions 10 samples PG-101A-048 48 reactions 20 samples PG-101A-048 48 reactions 40 samples PG-101A-048 48 reactions 40 samples PG-101A-048 48 reactions 40 samples PG-3802C-048 48 reactions 10 samples PG-3802C-048 48 reactions 20 samples PG-3802C-049 96 reactions 40 samples PG-3802C-049 96 reactions 10 samples PG-3802C-048 24 reactions 20 samples PG-3802C-049 96 reactions 40 samples PG-3802C-048 24 reactions 20 samples PG-3802C-048 24 reactions 20 samples PG-3802C-048 24 reactions 20 samples PG-3802C-049 48 reactions 20 samples PG-3802C-049 48 reactions 40 samples PG-3802C-048 24 reactions 40 samples PG-3802C-048 48 reactions 40 samples PG-3802C-054 48 reactions 40 samples PG-3802C-069 48 reactions 40 samples PG-3901C-048 48 reactions 20 samples PG-3901C-048 48 reactions 40 samples PG-3901C-048 48 reactions		PG-5101A-012	12 reactions	10 samples	USA (ASR)	Phenytion and Lamotrigine induced severe
PG-IC01A-048 48 reactions 40 samples PG-IC01A-012 12 reactions 10 samples PG-IC01A-024 24 reactions 20 samples PG-IC01A-048 48 reactions 40 samples PG-IC01A-048 48 reactions 40 samples PG-3802C-048 48 reactions 20 samples PG-3802C-048 48 reactions 20 samples PG-3802C-048 48 reactions 40 samples PG-3802C-048 48 reactions 40 samples PG-3802C-048 48 reactions 40 samples PG-3802C-048 24 reactions 10 samples PG-3802C-048 24 reactions 40 samples PG-3802C-048 24 reactions 10 samples PG-3802A-048 24 reactions 20 samples PG-3802A-048 24 reactions 40 samples PG-3802A-048 24 reactions 40 samples PG-3802A-048 24 reactions 40 samples PG-3802A-056 48 reactions 40 samples PG-3901C-048 48 reactions 20 samples PG-3901C-048 48 reactions 20 samples PG-3901C-048 48 reactions 20 samples PG-3901C-048 48 reactions 40 sam		PG-5101A-024	24 reactions	20 samples		
PG-IC01A-024 24 reactions 20 samples PG-IC01A-024 24 reactions 20 samples PG-IC01A-048 48 reactions 40 samples PG-3802C Detection Kit PG-3802C-024 24 reactions 10 samples PG-3802C-048 48 reactions 40 samples PG-3802C-096 96 reactions 40 samples PG-3802C-096 96 reactions 40 samples PG-3802C-096 96 reactions 10 samples PG-3802A-012 12 reactions 10 samples PG-3802A-012 12 reactions 20 samples PG-3802A-048 24 reactions 20 samples PG-3802A-096 48 reactions 40 samples PG-3802A-096 48 reactions 40 samples PG-3901C-024 24 reactions 10 samples PG-3901C-024 24 reactions 20 samples PG-3901C-048 48 reactions 20 samples PG-3901C-048 48 reactions 40 samples PG-3901C-048 48 reactions 20 samples PG-3901C-048 48 reactions 40 samples PG-3901C		PG-5101A-048	48 reactions	40 samples		
PG-IC01A-024 24 reactions 20 samples PG-IC01A-048 48 reactions 40 samples PG-3802C-024 24 reactions 10 samples PG-3802C-048 48 reactions 20 samples PG-3802C-048 48 reactions 40 samples PG-3802C-096 96 reactions 40 samples PG-3802C-096 96 reactions 20 samples PG-3802A-012 12 reactions 10 samples PG-3802A-012 12 reactions 20 samples PG-3802A-012 12 reactions 20 samples PG-3802A-0148 24 reactions 20 samples PG-3802A-096 48 reactions 40 samples PG-3901C-024 24 reactions 10 samples PG-3901C-024 24 reactions 20 samples PG-3901C-024 24 reactions 20 samples PG-3901C-096 96 reactions 40 sa		PG-IC01A-012	12 reactions	10 samples		ŭ .
PG3802 Detection Kit PG-3802C-024 24 reactions 10 samples RUO HLA-B*3802 gene has been found an association with Disease-modifying Anti-rheumatic drugs (DMARDs) induced severe cutaneous adverse reactions (SCARs). PG-3802C-096 PG-3802C-096 PG-3802A-012 12 reactions 10 samples PG-3802A-012 12 reactions 10 samples USA (ASR) HLA-B*3802 gene has been found an association with Disease-modifying Anti-rheumatic drugs (DMARDs) induced severe cutaneous adverse reactions (SCARs). PG-3802A-048 PG-3802A-096 48 reactions 40 samples PG-3901C-024 PG-3901C-024 PG-3901C-048 PG-3901C-096 PG-3901C-096 PG-3901A-012 PG-3901A-012 PG-3901A-048 PG-3		PG-IC01A-024	24 reactions	20 samples	USA (ASR)	
PG-3802C-048 48 reactions 20 samples PG-3802C-048 48 reactions 20 samples PG-3802C-096 96 reactions 40 samples PG-3802C-096 96 reactions 40 samples PG-3802A-012 12 reactions 10 samples PG-3802A-048 24 reactions 20 samples PG-3802A-048 24 reactions 40 samples PG-3802A-096 48 reactions 40 samples PG-3901C-024 24 reactions 10 samples PG-3901C-048 48 reactions 20 samples PG-3901C-048 48 reactions 20 samples PG-3901C-048 48 reactions 20 samples PG-3901C-048 48 reactions 40 samples PG-3901C-048 48 reactions 20 samples PG-3901C-048 48 reactions 40 sam		PG-IC01A-048	48 reactions	40 samples		
PG-3802C-048 48 reactions 20 samples RU0 with Disease-modifying Anti-rheumatic drugs (DMARDs) induced severe cutaneous adverse reactions (SCARs). PG-3802C-096 96 reactions 40 samples PG-3802A-012 12 reactions 10 samples PG-3802A-048 24 reactions 20 samples PG-3802A-096 48 reactions 40 samples PG-3802A-096 48 reactions 40 samples PG-3901C-024 24 reactions 10 samples PG-3901C-024 24 reactions 10 samples PG-3901C-048 48 reactions 20 samples PG-3901C-048 48 reactions 20 samples PG-3901C-048 48 reactions 40 samples		PG-3802C-024	24 reactions	10 samples	RUO	with Disease-modifying Anti-rheumatic drugs (DMARDs) induced severe cutaneous adverse
PG-3802C-096 96 reactions 40 samples PG-3802A-012 12 reactions 10 samples PG-3802A-012 12 reactions 20 samples PG-3802A-048 24 reactions 40 samples PG-3802A-096 48 reactions 40 samples PG-3901C-024 24 reactions 10 samples PG-3901C-048 48 reactions 20 samples PG-3901C-048 48 reactions 20 samples PG-3901C-096 96 reactions 40 sam		PG-3802C-048	48 reactions	20 samples		
PG3802 Detection Reagent PG-3802A-048 24 reactions 20 samples USA (ASR) USA (ASR) HLA-B*3802 gene has been found an association with Disease-modifying Anti-rheumatic drugs (DMARDs) induced severe cutaneous adverse reactions (SCARs). PG-3801C-024 PG-3901C-024 PG-3901C-048 PG-3901C-096 PG-3901C-096 PG-3901C-096 PG-3901A-012 PG-3901A-012 PG-3901A-048		PG-3802C-096	96 reactions	40 samples		
PG3802 Detection Reagent PG-3802A-048 24 reactions 20 samples USA (ASR) With Disease-modifying Anti-rheumatic drugs (DMARDs) induced severe cutaneous adverse reactions (SCARs). PG-3802A-096 48 reactions 10 samples PG-3901C-024 24 reactions 20 samples RU0 HLA-B*3901 gene has been found an association with Disease-modifying Anti-rheumatic drugs (DMARDs) induced severe cutaneous adverse reactions (SCARs). PG-3901C-048 48 reactions 20 samples RU0 PG-3901C-048 PG-3901C-096 96 reactions 40 samples PG-3901A-012 12 reactions 10 samples HLA-B*3901 gene has been found an association with Disease-modifying Anti-rheumatic drugs (DMARDs) induced severe cutaneous adverse reactions (SCARs).		PG-3802A-012	12 reactions	10 samples		with Disease-modifying Anti-rheumatic drugs (DMARDs) induced severe cutaneous adverse
PG-3802A-096 48 reactions 40 samples PG-3901C-024 24 reactions 10 samples PG-3901C-048 48 reactions 20 samples PG-3901C-096 96 reactions 40 samples PG-3901C-096 96 reactions 10 samples PG-3901A-012 12 reactions 10 samples PG-3901A-048 24 reactions 20 samples		PG-3802A-048	24 reactions	20 samples	USA (ASR)	
PG3901 Detection Kit PG-3901C-048 48 reactions 20 samples RU0 HLA-B*3901 gene has been found an association with Disease-modifying Anti-rheumatic drugs (DMARDs) induced severe cutaneous adverse reactions (SCARs). PG-3901C-096 96 reactions 10 samples PG-3901A-012 12 reactions 10 samples HLA-B*3901 gene has been found an association with Disease-modifying Anti-rheumatic drugs (DMARDs) induced severe cutaneous adverse reactions USA (ASR) Disease-modifying Anti-rheumatic drugs (DMARDs) induced severe cutaneous adverse reactions	- Sercetion reagent	PG-3802A-096	48 reactions	40 samples		
PG-3901C-048 48 reactions 20 samples RUO Disease-modifying Anti-rheumatic drugs (DMARDs) induced severe cutaneous adverse reactions (SCARs). PG-3901C-096 96 reactions 40 samples PG-3901A-012 12 reactions 10 samples PG-3901A-012 12 reactions 20 samples PG-3901A-048 24 reactions 20 samples USA (ASR) Disease-modifying Anti-rheumatic drugs (DMARDs) induced severe cutaneous adverse reactions induced severe cutaneous adverse reactions		PG-3901C-024	24 reactions	10 samples		Disease-modifying Anti-rheumatic drugs (DMARDs) induced severe cutaneous adverse reactions
PG-3901C-096 96 reactions 40 samples PG-3901A-012 12 reactions 10 samples PG-3901A-048 24 reactions 20 samples USA (ASR) (SCARs). HLA-B*3901 gene has been found an association with Disease-modifying Anti-rheumatic drugs (DMARDs) induced severe cutaneous adverse reactions		PG-3901C-048	48 reactions	20 samples	RUO	
PG3901 Detection Reagent PG-3901A-048 PG-390		PG-3901C-096	96 reactions	40 samples		
PG3901 Detection Reagent PG-3901A-048 24 reactions 20 samples USA (ASR) Disease-modifying Anti-rheumatic drugs (DMARDs) induced severe cutaneous adverse reactions		PG-3901A-012	12 reactions	10 samples	USA (ASR)	Disease-modifying Anti-rheumatic drugs (DMARDs)
		PG-3901A-048	24 reactions	20 samples		
PG-3901A-096 48 reactions 40 samples (SCARs).		PG-3901A-096	48 reactions	40 samples		

HLA Gene Associate Disease

Product Name	Catalog #	Pack Size	Sample Size	Regulation	Description
	PG-0602C-024	24 reactions	10 samples		The HLA-DQB1*06:02 allele is strongly associated with Narcolepsy. Narcolepsy is a sleep disorder associated with invalidating excessive daytime sleepiness and cataplexy. Greater than 99% of affected Caucasians
PG0602 Detection Kit	PG-0602C-048	48 reactions	20 samples	RUO	
	PG-0602C-096	96 reactions	40 samples		with cataplexy have the HLA-DQB1*06:02 allele.
	PG-0602A-012	12 reactions	10 samples	USA (ASR)	The HLA-DQB1*06:02 allele is strongly associated with Narcolepsy. Narcolepsy is a sleep disorder associated with invalidating excessive daytime sleepiness and cataplexy. Greater than 99% of affected Caucasians with cataplexy have the HLA-DQB1*06:02 allele.
PG0602 Detection Reagent	PG-0602A-024	24 reactions	20 samples		
	PG-0302A-048	48 reactions	40 samples		
	PG-B27C-024	24 reactions	10 samples	Taiwan FDA Thailand FDA CE IVD	The presence of HLA-B*27 allele is strongly associated with Ankylosing Spondylitis (AS) and a few other rheumatic disorders (Reiter's syndrome, acute anterior uveitis, and inflammatory bow.)
PG27 Detection Kit	PG-B27C-048	48 reactions	20 samples		
	PG-B27C-096	96 reactions	40 samples		
PG27 Detection Reagent	PG-B27A-012	12 reactions	10 samples	USA (ASR)	The presence of HLA-B*27 allele is strongly associated with Ankylosing Spondylitis (AS) and a few other rheumatic disorders (Reiter's syndrome, acute anterior uveitis, and inflammatory bow.)
	PG- B27A-024	24 reactions	20 samples		
	PG- B27A-048	48 reactions	40 samples		

Metabolism

Drug Metabolism

Drug metabolism has been recognized as the most important part to evaluate the real factor for drug efficiency. Drug metabolism is the metabolic breakdown of drugs by living organisms, usually through specialized enzymatic systems modulated by genes. Many of the major pharmacokinetic interactions between drugs are due to hepatic cvtochrome P450 (P450 or CYP) enzymes being affected by previous administration of other drugs. The ability of CYP enzymes can be illustrated by genotyping.

Product Name	Catalog #	Pack Size	Sample Size	Regulation	Description
	PG-0430C-012	12 reactions	10 samples		CYP2C9*2(0430) SNP has been found a strong linkage with the maintain dosage of Warfarin, a wide use anticoagulant. To test the different SNP type of VKORC1-1639 with CYP2C9*2(0430) and CYP2C9*3(1075) can help physician adjust the starting dose of warfarin and then quickly reach the
PG0430	PG-0430C-024	24 reactions	20 samples	Taiwan FDA Singapore HSA	
Detection Kit	PG-0430C-048	48 reactions	40 samples	Thailand FDA CE IVD	
	PG-0430C-096	96 reactions	80 samples		maintain dose.
	PG-0430A-012	12 reactions	10 samples		CYP2C9*2(0430) SNP has been found a strong linkage with the maintain dosage of Warfarin, a wide
PG0430 Detection Reagent	PG-0430A-024	24 reactions	20 samples	USA (ASR)	use anticoagulant. To test the different SNP type of VKORC1-1639 with CYP2C9*2(0430) and CYP2C9*3(1075) can help physician adjust the starting dose of warfarin and then quickly reach the maintain dose.
	PG-0430A-048	48 reactions	40 samples		
	PG-1075C-012	12 reactions	10 samples	Taiwan FDA Singapore HSA Thailand FDA CE IVD	CYP2C9*3(1075) SNP has been found a strong linkage with the maintain dosage of Warfarin, a wide use anticoagulant. To test the different SNP type of VKORC1-1639 with CYP2C9*2(0430) and CYP2C9*3(1075) can help physician adjust the starting dose of warfarin and then quickly reach the maintain dose.
PG1075	PG-1075C-024	24 reactions	20 samples		
Detection Kit	PG-1075C-048	48 reactions	40 samples		
	PG-1075C-096	96 reactions	80 samples		
	PG-1075A-012	12 reactions	10 samples	USA (ASR)	CYP2C9*3(1075) SNP has been found a strong linkage with the maintain dosage of Warfarin, a wide use anticoagulant. To test the different SNP type of VKORC1-1639 with CYP2C9*2(0430) and CYP2C9*3(1075) can help physician adjust the starting dose of warfarin and then quickly reach the maintain dose.
PG1075 Detection Reagent	PG-1075A-024	24 reactions	20 samples		
	PG-1075A-048	48 reactions	40 samples		
PG1639 Detection Kit	PG-1639C-012	12 reactions	10 samples	Taiwan FDA Singapore HSA Thailand FDA CE IVD	VKORC1-1639 SNP has been found a strong linkage with the maintain dosage of Warfarin, a wide use anticoagulant. To test the different SNP type of VKORC1-1639 with CYP2C9*2(0430) and CYP2C9*3(1075) can help physician adjust the starting dose of warfarin and then quickly reach the maintain dose.
	PG-1639C-024	24 reactions	20 samples		
	PG-1639C-048	48 reactions	40 samples		
	PG-1639C-096	96 reactions	80 samples		


Product Name	Catalog #	Pack Size	Sample Size	Regulation	Description
	PG-1639A-012	12 reactions	10 samples		VKORC1-1639 SNP has been found a strong linkage with the maintain dosage of Warfarin, a wide use anticoagulant. To test the different SNP type of VKORC1-1639 with CYP2C9*2(0430) and CYP2C9*3(1075) can help physician adjust the
PG1639 Detection Reagent	PG-1639A-024	24 reactions	20 samples	USA (ASR)	
	PG-1639A-048	48 reactions	40 samples		starting dose of warfarin and then quickly reach the maintain dose.
	PG-0681C-012	12 reactions	10 samples		Clopidogrel is an antiplatelet agent which prevents platelet aggregation and is used for treatment of
PG0681 Detection Kit	PG-0681C-024	24 reactions	20 samples	The Stand FDA	cardiovascular disease. For Clopidogrel to work, enzymes in the liver (particularly CYP2C19) must convert the drug to its active form. People with genotypes CYP2C19*2(0681) or CYP2C19*3(0636) are poor metabolizer (PM) of the drug and should avoid taking Clopidogrel.
	PG-0681C-048	48 reactions	40 samples	Thailand FDA	
	PG-0681C-096	96 reactions	80 samples		
	PG-0681A-012	12 reactions	10 samples	USA (ASR)	Clopidogrel is an antiplatelet agent which prevents platelet aggregation and is used for treatment of cardiovascular disease. For Clopidogrel to work, enzymes in the liver (particularly CYP2C19) must convert the drug to its active form. People with genotypes CYP2C19*2(0681) or CYP2C19*3(0636) are poor metabolizer (PM) of the drug and should avoid taking Clopidogrel.
PG0681 Detection Reagent	PG-0681A-024	24 reactions	20 samples		
	PG-0681A-048	48 reactions	40 samples		
	PG-0636C-012	12 reactions	10 samples	Thailand FDA	Clopidogrel is an antiplatelet agent which prevents platelet aggregation and is used for treatment of cardiovascular disease. For Clopidogrel to work, enzymes in the liver (particularly CYP2C19) must convert the drug to its active form. People with genotypes CYP2C19*2(0681) or CYP2C19*3(0636) are poor metabolizer (PM) of the drug and should avoid taking Clopidogrel.
PG0636	PG-0636C-024	24 reactions	20 samples		
Detection Kit	PG-0636C-048	48 reactions	40 samples		
	PG-0636C-096	96 reactions	80 samples		
PG0636 Detection Kit	PG-0636A-012	12 reactions	10 samples	USA (ASR)	Clopidogrel is an antiplatelet agent which prevents platelet aggregation and is used for treatment of cardiovascular disease. For Clopidogrel to work, enzymes in the liver (particularly CYP2C19) must convert the drug to its active form. People with genotypes CYP2C19*2(0681) or CYP2C19*3(0636) are poor metabolizer (PM) of the drug and should avoid taking Clopidogrel.
	PG-0636A-024	24 reactions	20 samples		
	PG-0636A-048	48 reactions	40 samples		

Molecular Diagnostics

Product Name	Catalog #	Pack Size	Sample Size	Regulation	Description
SARS-CoV-2 Detection Kit	PG-CoV2C- 096	96 reactions	94 samples	CE IVD	The SARS-CoV-2 Detection Kit is a TaqMan [™] real-time RT-PCR assay for the qualitative detection of SARS-CoV-2 RNA. The kit includes two assays that target SARS-CoV-2 RdRp and N gene, and one internal control assay that target human RNase P gene.
SARS-CoV-2 Essence Detection Kit	PG-CoV2E-096	96 reactions	94 samples	CE IVD	The SARS-CoV-2 Essence Detection Kit is a TaqMan [™] real-time RT-PCR assay for the qualitative detection of SARS-CoV-2 RNA The kit includes two assays that target SARS-CoV-2 RdRp gene and human RNase P gene as an internal control.

IVD CDMO Service

Contract Development and Manufacturing Organization (CDMO) is to provide comprehensive services from product development through product manufacturing in medical field.



Pharmigene CDMO service can help you

- From ideas to products.
- Prototype development.
- Materials purchasing & qualification.
- Product verification & validation.
- Scale-up manufacturing.
- Regulatory consultation.

Flexible, Tailored Solutions

You can choose the services you need—no unnecessary costs, just easy in-and-out service.

Quality Management System

Manufacturer Plant has obtained ISO13485, Taiwan (QMS) and Korea (KGMP) certificates.



Taiwan QMS



ISO 13485



Korea GMP

Why Choose Pharmigene?

PharmiGENE is your most flexible and cost-effective choice.

- Expertise You Can Trust Extensive experience in R&D and manufacturing of molecular diagnostic products, enzyme-linked assays, in-situ hybridization products, cell culture media, and general-purpose reagents
- Diverse Capabilities From genes, enzymes, stains, and culture media.... we offer a wide variety of products to meet your needs.
- Cost-Effective Solutions The best quality at a competitive price.
- Flexible Production Capacity-Whether you need small batches or large-scale production, we can accommodate your requirements efficiently.

Our CDMO Product

Application Field

Infectious disease detection Cancer detection panel Cancer prognosis detection Cancer drug evaluation Histology Cell therapy

Product Category

IVD RUO

Technology Platform

Fluorescence probe ELISA qPCR NGS

